FDA approves Avanir’s Onzetra Xsail

SILVER SPRING, Md. — Avanir Pharmaceuticals announced Friday that the Food and Drug Administration had approved its new migraine treatment Onzetra Xsail (sumatriptan) nasal powder. The drug is delivered via the Xsail breath-powered delivery device, allowing intranasal dosing of the most commonly prescribed migraine treatment. 

 

"While there are many acute migraine treatment options available, more than 70% of patients are not fully satisfied with their current migraine treatment. Given this high dissatisfaction, there remains an unmet need to provide patients with fast-acting, well tolerated therapies that deliver consistent relief," said Stewart Tepper, M.D., professor of neurology at the Geisel School of Medicine at Dartmouth.

 

This marks the second approved product from Avanir.